glp 1 drugs and birth control GLP-1 interactions: Here's what you need to know GLP-1 and Birth Control: Interaction

Glucose-dependent secretion

[33, 34, 35, 36] Mechanism: Typically pre-renal, occurring in the setting of volume depletion from GI losses (nausea, vomiting, diarrhea, reduced oral intake) More frequently seen at higher, obesity-level doses Although generally reno-protective long term, post-marketing data describe acute rises in creatinine following days to weeks of significant GI symptoms Risk factors: Underlying chronic kidney disease Concomitant use of ACE inhibitors, ARBs, diuretics, or SGLT2 inhibitors ED Management: IV fluids Hold GLP-1 and contributing medications Usually reversible with supportive care Future Directions GLP-1 receptor agonists are rapidly evolving beyond their original indications in diabetes and obesity

[Google Scholar] 25.Valverde I., Rigopoulou D., Marco J., Faloona G.R., Unger R.H

Practice patterns and perspectives of the off-label use of GLP-1 agonists for cosmetic weight loss

This approach pairs convenience with professional support, ensuring patients have the tools they need to stick with their treatment plans

The STRIDE trial evaluated semaglutide in patients with T2DM and PAD, finding a 13% improvement in maximum walking distance and a significant increase in ankle-brachial index, indicating improved perfusion